Business
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University
About this update from Abeona Therapeutics Inc.
[{"type":"text","content":"CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. “Activation of NewYork-Presbyterian/Columbia University Irving Medical Center as our fifth QTC significantly expands patient access to ZEVASKYN in the New York metropolitan area and across the Northeast,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. “Partnering with an institution recognized globally for its leadership in genetic medicines and long history in managing blistering skin disorders means that our patients will be supported by world-class clinical expertise throughout their treatment journey.” Aimee Payne, MD, PhD, the Herbert and Florence Irving Professor and Chair of Dermatology at Columbia University Vagelos College of Physicians and Surgeons and Dermatologist-in-Chief at NewYork-Presbyterian, said, “Integrating this gene therapy underscores NewYork-Presbyterian and Columbia’s leadership in precision medicine and our deep commitment to the epidermolysis bullosa community. Our multidisciplinary model is designed to support these patients through a lifetime of care—including the critical transition from pediatric to adult medicine. For families navigating the daily burden of recessive dystrophic epidermolysis bullosa, this is more than a new option for healing skin—it is a vital step toward restoring their confidence, mobility, and hope.” For more information on how to access ZEVASKYN and learn about patient support services offered through Abeona Assist®, Abeona’s comprehensive patient support program, visit www.abeonaassist.com, call 1-855-ABEONA-1 (1-855-223-6621) or email [email protected]. Abeona Assist offers personalized support, including helping eligible patients understand their insurance benefits and financial assistance options, and providing travel and logistical assistance. About recessive dystrophic epidermolysis bullosaRecessive dystrophic epidermolysis bullosa (RDEB), a rare blistering disorder without a cure, is characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of lif...